By not acknowledging Anavex accomplishments to date, which can be readily seen by the lack of respect offered to Dr. Missling and Company, you undermine your assertions.
Why should long time investors, or anyone, listen to rhetoric generated by such a questionable source?
Dr. Missling and Company are advancing the benefits of the S-1R receptor, as no one else has come close to doing. The Sigma One Platform will support a new era in CNS therapeutics.
Rushing this process seems less advisable than following a sensible plan.